litlas
ログインアカウント作成

Narikazu Boku

1997–2025 年に発表

161
論文数
23,966
被引用数
77
h 指数
149
i10 指数

被引用数

Narikazu Boku の年別被引用数1997 年: 被引用 4 件1999 年: 被引用 6 件2000 年: 被引用 8 件2001 年: 被引用 7 件2002 年: 被引用 17 件2003 年: 被引用 22 件2004 年: 被引用 31 件2005 年: 被引用 43 件2006 年: 被引用 56 件2007 年: 被引用 29 件2008 年: 被引用 66 件2009 年: 被引用 75 件2010 年: 被引用 54 件2011 年: 被引用 53 件2012 年: 被引用 51 件2013 年: 被引用 83 件2014 年: 被引用 91 件2015 年: 被引用 107 件2016 年: 被引用 98 件2017 年: 被引用 120 件2018 年: 被引用 153 件2019 年: 被引用 763 件2020 年: 被引用 1,005 件2021 年: 被引用 937 件2022 年: 被引用 697 件2023 年: 被引用 518 件2024 年: 被引用 832 件2025 年: 被引用 364 件2026 年: 被引用 17 件1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図日本: 引用元論文 1,644 件、この内訳の 22.4%中国: 引用元論文 1,323 件、この内訳の 18%アメリカ合衆国: 引用元論文 1,057 件、この内訳の 14.4%イタリア: 引用元論文 330 件、この内訳の 4.5%韓国: 引用元論文 319 件、この内訳の 4.3%イギリス: 引用元論文 287 件、この内訳の 3.9%ドイツ: 引用元論文 266 件、この内訳の 3.6%フランス: 引用元論文 183 件、この内訳の 2.5%オランダ: 引用元論文 162 件、この内訳の 2.2%スペイン: 引用元論文 160 件、この内訳の 2.2%台湾: 引用元論文 117 件、この内訳の 1.6%スイス: 引用元論文 110 件、この内訳の 1.5%
0%22.4%その他 18.9%

機関

分野

  • Medicine85%
  • Biochemistry, Genetics and Molecular Biology9.8%
  • Immunology and Microbiology2.9%
  • Neuroscience0.5%
  • Engineering0.4%
  • Computer Science0.2%
  • その他1.2%

トピック

  • Gastric Cancer Management and Outcomes11.9%
  • Cancer Immunotherapy and Biomarkers7.1%
  • Esophageal Cancer Research and Treatment5.8%
  • Pancreatic and Hepatic Oncology Research4.6%
  • Colorectal Cancer Surgical Treatments3.8%
  • Colorectal Cancer Treatments and Studies3.6%
  • その他63.2%

共著者

全論文

検索で開く
  1. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

    著者: Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu, Do‐Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik‐Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen‐Shi Chen, Li‐Yuan Bai, Sung‐Yong Oh, Yasuhiro Choda, Hisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara, Narikazu Boku - The Lancet Oncology 2022 被引用: 768

  2. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, Min‐Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen‐Shi Chen, Kei Muro, Won Ki Kang, Kun‐Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun‐Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chìn, Do‐Youn Oh, Keiko Minashi, Y. Choi, Masahiro Tsuda, Li‐Tzong Chen - The Lancet 2017 被引用: 2,279

  3. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

    著者: Japanese Society for Cancer of the Colon and Rectum, Toshiaki Watanabe, Kei Muro, Yoichi Ajioka, Yojiro Hashiguchi, Yoshinori Ito, Yutaka Saito, Tetsuya Hamaguchi, Hideyuki Ishida, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Hiroshi Kawano, Yusuke Kinugasa, Norihiro Kokudo, Keiko Murofushi, Takako Eguchi Nakajima, Shiro Oka, Yoshiharu Sakai, Akihito Tsuji, Keisuke Uehara, Hideki Ueno, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Narikazu Boku, Takahiro Fujimori, Michio Itabashi, Nobuo Koinuma, Takayuki Morita, Genichi Nishimura, Yuh Sakata, Yasuhiro Shimada, Keiichi Takahashi, Shinji Tanaka, Osamu Tsuruta, Toshiharu Yamaguchi, Naohiko YAMAGUCHI, Toshiaki Tanaka, Kenjiro Kotake, Kenichi Sugihara - International Journal of Clinical Oncology 2017 被引用: 2,490

  4. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

    著者: Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi, Yukiyasu Okamura, Masaru Konishi, Ippei Matsumoto, Yuji Kaneoka, Yasuhiro Shimizu, Shoji Nakamori, Hirohiko Sakamoto, Soichiro Morinaga, Osamu Kainuma, Koji Imai, Naohiro Sata, Shoichi Hishinuma, Hitoshi Ojima, Ryuzo Yamaguchi, Satoshi Hirano, Takeshi Sudo, Yasuo Ohashi - The Lancet 2016 被引用: 1,126

  5. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

    著者: Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Yoshiki Horie, Akihito Tsuji, Toshikazu Moriwaki, Hiroaki Tanioka, Katsunori Shinozaki, Keita Uchino, Hirofumi Yasui, Hiroshi Tsukuda, Kazuhiro Nishikawa, Hiroyasu Ishida, Takeharu Yamanaka, Kentaro Yamazaki, Shuichi Hironaka, Taito Esaki, Narikazu Boku, Ichinosuke Hyodo, Kei Muro - Journal of Clinical Oncology 2020 被引用: 197

  6. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

    著者: Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem, Kuhn‐Uk Lee, Lucjan Wyrwicz, Michael Schenker, María Alsina, Min‐Hee Ryu, Hyun Cheol Chung, Ludovic Evesque, Salah-Eddin Al-Batran, Se Hoon Park, M. Lichinitser, Narikazu Boku, Markus Moehler, Janet Hong, Hua Xiong, Roland Hallwachs, Ilaria Conti, Julien Taı̈eb - Annals of Oncology 2018 被引用: 503

  7. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

    著者: Markus Moehler, Mikhail Dvorkin, Narikazu Boku, Mustafa Özgüroğlu, Min‐Hee Ryu, Alina Muntean, Sara Lonardi, Marina Nechaeva, Arinilda Campos Bragagnoli, Hasan Şenol Çoşkun, Antonio Cubillo Gracián, Toshimi Takano, Rachel Wong, Howard Safran, Gina M. Vaccaro, Zev A. Wainberg, Matthew R. Silver, Huiling Xiong, Janet Hong, Julien Taı̈eb, Yung‐Jue Bang - Journal of Clinical Oncology 2020 被引用: 223

  8. Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

    著者: Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui, Tomohiro Nishina, Masahiro Tsuda, Takehiko Tsumura, Naotoshi Sugimoto, Hideki Shimodaira, Shinya Tokunaga, Toshikazu Moriwaki, Taito Esaki, Michitaka Nagase, Kazumasa Fujitani, Kensei Yamaguchi, Takashi Ura, Yasuo Hamamoto, Satoshi Morita, Isamu Okamoto, Narikazu Boku, Ichinosuke Hyodo - Journal of Clinical Oncology 2013 被引用: 559

  9. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities

    著者: Yosuke Tanaka, Fumiko Chiwaki, Shinya Kojima, Masahito Kawazu, Masayuki Komatsu, Toshihide Ueno, Satoshi Inoue, Shigeki Sekine, Keisuke Matsusaki, Hiromichi Matsushita, Narikazu Boku, Yae Kanai, Yasushi Yatabe, Hiroki Sasaki, Hiroyuki Mano - Nature Cancer 2021 被引用: 92

  10. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    著者: Li‐Tzong Chen, Taroh Satoh, Min‐Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen‐Shi Chen, Kei Muro, Won Ki Kang, Kun‐Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun‐Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chìn, Do‐Youn Oh, Keiko Minashi, Y. Choi, Masahiro Tsuda, Hiroki Sameshima, Yoon‐Koo Kang, Narikazu Boku - Gastric Cancer 2019 被引用: 231

  11. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial

    著者: Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Hitoshi Katai, Takaki Yoshikawa, Seiji Ito, Masahide Kaji, Yutaka Kimura, Motohiro Hirao, Makoto Yamada, Akira Kurita, Masakazu Takagi, Sang‐Woong Lee, Akinori Takagane, Hiroshi Yabusaki, Jun Hihara, Narikazu Boku, Takeshi Sano, Mitsuru Sasako - Gastric Cancer 2020 被引用: 170

  12. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

    著者: Yoon‐Koo Kang, Masanori Terashima, Young‐Woo Kim, Narikazu Boku, Hyun Cheol Chung, Jen‐Shi Chen, Jiafu Ji, Ta-Sen Yeh, Li‐Tzong Chen, Min‐Hee Ryu, Jong Gwang Kim, Takeshi Omori, Sun Young Rha, Tae Yong Kim, Keun Won Ryu, Shinichi Sakuramoto, Yasunori Nishida, Norimasa Fukushima, Takanobu Yamada, Li‐Yuan Bai, Yoshinori Hirashima, Shunsuke Hagihara, Takashi Nakada, Mitsuru Sasako - ˜The œLancet. Gastroenterology & hepatology 2024 被引用: 75

  13. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

    著者: Narikazu Boku, Taroh Satoh, Min‐Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen‐Shi Chen, Kei Muro, Won Ki Kang, Kun‐Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun‐Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chìn, Do‐Youn Oh, Keiko Minashi, Y. Choi, Masahiro Tsuda, Taihei Nishiyama, Li‐Tzong Chen, Yoon‐Koo Kang - Gastric Cancer 2021 被引用: 123

  14. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

    著者: Yung‐Jue Bang, Rui‐Hua Xu, Keisho Chìn, Keun‐Wook Lee, Se Hoon Park, Sun Young Rha, Lin Shen, Shukui Qin, Nong Xu, Seock‐Ah Im, Gershon Y. Locker, Philip Rowe, Xiaojin Shi, Darren Hodgson, Yu-Zhen Liu, Narikazu Boku - The Lancet Oncology 2017 被引用: 291

  15. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

    著者: K. Yamazaki, Michitaka Nagase, H Tamagawa, Shinya Ueda, Takao Tamura, K. Murata, Takako Eguchi Nakajima, Eishi Baba, Masahiro Tsuda, Toshikazu Moriwaki, Taito Esaki, Yasushi Tsuji, Kei Muro, Koichi Taira, Tadamichi Denda, Sadao Funai, Katsunori Shinozaki, Hitoshi Yamashita, Naotoshi Sugimoto, Tatsuya Okuno, Tomohiro Nishina, M. Umeki, Takayuki Kurimoto, Tetsuji Takayama, Akihito Tsuji, Miki Yoshida, A. Hosokawa, Yoshihiro Shibata, Koichi Suyama, Masaru Okabe, Koichi Suzuki, Narihito Seki, Kentaro Kawakami, Mikio Sato, Koshi Fujikawa, T. Hirashima, Takaya Shimura, K. Taku, Toshio Otsuji, F. Tamura, Eiji Shinozaki, Kazutaka Nakashima, Hiroki Hara, Takahiro Tsushima, Masahiko Ando, Satoshi Morita, Narikazu Boku, Ichinosuke Hyodo - Annals of Oncology 2016 被引用: 282

  16. HER2-positive gastric cancer

    著者: Narikazu Boku - Gastric Cancer 2013 被引用: 362

  17. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial

    著者: Yoon‐Koo Kang, Keisho Chìn, Hyun Cheol Chung, Shigenori Kadowaki, Sang Cheul Oh, Norisuke Nakayama, Keun‐Wook Lee, Hiroki Hara, Ik-Joo Chung, Masahiro Tsuda, Se Hoon Park, Hisashi Hosaka, Shuichi Hironaka, Yoshinori Miyata, Min‐Hee Ryu, Hideo Baba, Ichinosuke Hyodo, Yung‐Jue Bang, Narikazu Boku - The Lancet Oncology 2020 被引用: 77

  18. Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

    著者: Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, T Shimamura, Masayuki Sho, Masayuki Kitano, Ann‐Lii Cheng, Kazuhiro Mizumoto, Jen‐Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Satō, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka - Journal of Clinical Oncology 2013 被引用: 633

  19. ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.

    著者: Masanori Terashima, Yoon‐Koo Kang, Young‐Woo Kim, Narikazu Boku, Hyun Cheol Chung, Jen‐Shi Chen, Jiafu Ji, Ta‐Sen Yeh, Li‐Tzong Chen, Min‐Hee Ryu, Jong Gwang Kim, Takeshi Omori, Sun Young Rha, Tae‐Yong Kim, Keun Won Ryu, Shinichi Sakuramoto, Yasunori Nishida, Norimasa Fukushima, Takanobu Yamada, Mitsuru Sasako - Journal of Clinical Oncology 2023 被引用: 41

  20. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

    著者: Yasuhide Yamada, Narikazu Boku, Junki Mizusawa, Satoru Iwasa, Shigenori Kadowaki, Norisuke Nakayama, Mizutomo Azuma, Takeshi Sakamoto, Kohei Shitara, Takao Tamura, Keisho Chìn, Hiroaki Hata, Mikihito Nakamori, Hiroki Hara, Hirofumi Yasui, Hiroshi Katayama, Haruhiko Fukuda, Takaki Yoshikawa, Mitsuru Sasako, Masanori Terashima - ˜The œLancet. Gastroenterology & hepatology 2019 被引用: 125

  21. Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer

    著者: Yasuyuki Takamizawa, Dai Shida, Narikazu Boku, Yuya Nakamura, Yuka Ahiko, Takefumi Yoshida, Taro Tanabe, Atsuo Takashima, Yukihide Kanemitsu - BMC Cancer 2020 被引用: 57

  22. Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): a study protocol

    著者: Rie Makuuchi, Masanori Terashima, Mitsumi Terada, Junki Mizusawa, Ryosuke Kita, Masanori Tokunaga, Takeshi Omori, Toshiyasu Ojima, Kazuhisa Ehara, Masaya Watanabe, Yoshitomo Yanagimoto, Souya Nunobe, Takahiro Kinoshita, Seiji Ito, Yasunori Nishida, Jun Hihara, Narikazu Boku, Yukinori Kurokawa, Takaki Yoshikawa - BMC Cancer 2023 被引用: 35

  23. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

    著者: Toshiaki Watanabe, Michio Itabashi, Yasuhiro Shimada, Shinji Tanaka, Yoshinori Ito, Yoichi Ajioka, Tetsuya Hamaguchi, Ichinosuke Hyodo, Masahiro Igarashi, Hideyuki Ishida, Soichiro Ishihara, Megumi Ishiguro, Yukihide Kanemitsu, Norihiro Kokudo, Kei Muro, Atsushi Ochiai, Masahiko Oguchi, Yasuo Ohkura, Yutaka Saito, Yoshiharu Sakai, Hideki Ueno, Takayuki Yoshino, Narikazu Boku, Takahiro Fujimori, Nobuo Koinuma, Takayuki Morita, Genichi Nishimura, Yuh Sakata, Keiichi Takahashi, Osamu Tsuruta, Toshiharu Yamaguchi, Masahiro Yoshida, Naohiko YAMAGUCHI, Kenjiro Kotake, Kenichi Sugihara, Japanese Society for Cancer of the Colon and Rectum - International Journal of Clinical Oncology 2015 被引用: 600

  24. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

    著者: Jan H. Beumer, Edward Chu, Carmen J. Allegra, Yusuke Tanigawara, G. Milano, Robert B. Diasio, Tae Won Kim, Ron H.J. Mathijssen, Li Zhang, Dirk Arnold, Katsuki Muneoka, Narikazu Boku, Markus Joerger - Clinical Pharmacology & Therapeutics 2018 被引用: 126